• Home
  • Stock News
  • Privacy Policy
  • Email Whitelisting
No Result
View All Result
Dividend Stocks Report
No Result
View All Result
Home Stock News

Pfizer starts submitting data for FDA emergency approval of vaccine for kids under 5

by
February 1, 2022
in Stock News
0
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Related Posts

Home sales spike 14.5% in February as the median price drops for the first time in over a decade

Cathie Wood says rising rates hit her strategy like an earthquake and cyclical stocks are next

Potentially deadly fungus is spreading at an ‘alarming rate,’ CDC says

Bitcoin, ether build on recent gains as investors await Fed rate hike decision

In this article

BNTX

PFE

A student gets help with his mask from transitional kindergarten teacher Annette Cuccarese during the first day of classes at Tustin Ranch Elementary School in Tustin, CA on Wednesday, August 11, 2021.
Paul Bersebach | MediaNews Group | Getty Images

Pfizer and BioNTech on Tuesday started submitting data for the Food and Drug Administration to grant emergency approval for kids under 5 to receive their vaccine.

The companies said the FDA requested that they start submitting data for the authorization of the first two doses of what will eventually be a three-dose vaccine for children six months through 4 years of age. Pfizer and BioNTech said data on the third dose will be completed and submitted to the FDA in the coming months.

Pfizer and BioNTech started submitting their application for emergency approval in response to the “urgent public health need” of younger children as the omicron variant has resulted in a spike in hospitalizations in this age group.

“As hospitalizations of children under 5 due to COVID-19 have soared, our mutual goal with the FDA is to prepare for future variant surges and provide parents with an option to help protect their children from this virus,” said Pfizer CEO Albert Bourla in a statement.

Bourla said kids under 5 will ultimately need a third dose to have the best protection against omicron and future Covid variants. By getting the first two-doses FDA authorized, parents can start getting their kids vaccinated while they wait for the third dose, Bourla said. Pfizer and BioNTech expect to complete their application for emergency approval of the first two-doses in the coming days.

Toddlers and kids under 5 years old are the last age group left that is not eligible for vaccination. The FDA is expected to fast track the approval process for 6-month to 4-year-olds like it has for other age groups. Once approved, pediatricians will be able to administer shots within a matter of days.

Parents are anxiously awaiting the vaccine for younger children as the omicron variant sweeps across the nation, causing an unprecedented wave of infection over the past month.

Although children are at much lower risk of developing severe illness from Covid compared to adults, their hospitalizations with the virus have increased during the recent surge of infections, raising concerns about the long-term implications for kids’ health.

“Sadly, we are seeing the rates of hospitalizations increasing for children zero to 4, children who are not yet currently eligible for Covid-19 vaccination,” Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, told reporters in January.

White House chief medical advisor Dr. Anthony Fauci said last month that he hoped the FDA would authorize the vaccine for kids sometime in February. Fauci said at the time that younger children would likely need a three-dose vaccine.

CNBC Health & Science

Read CNBC’s latest global coverage of the Covid pandemic:

WHO says the new omicron subvariant doesn’t appear to be more severe than the original

U.S. Covid fatalities reach highest level in a year as omicron cases subside

Why you may need an omicron-specific vaccine even after this Covid surge ends, Moderna’s top doctor says

Moderna receives full U.S. approval for its Covid vaccine

Two New York nurses charged with forging Covid vaccine cards to earn more than $1.5 million

The latest Covid variant is 1.5 times more contagious than omicron and already circulating in almost half of U.S. states

60 million U.S. households have ordered free Covid tests, White House says

Moderna starts clinical trial of booster shot targeting omicron Covid variant

Pfizer amended its clinical trial in December to study a third shot after two doses of its 3 microgram vaccine did not produce an adequate immune response in children 2 to 4 years old. Adults receive two 30 microgram doses in their primary series of shots.

Pfizer’s vaccine researcher, Dr. Alejandra Gurtman, said last month the drugmaker planned to have the data for kids under 5 ready by the end of March or beginning of April. However, a group of 250 doctors sent a letter last month asking the FDA to cut red tape and authorize the 3 microgram dose for children. The doctors said it was unethical to not give parents the option to vaccinate younger children as the pandemic rages across the country.

“As children re-enter daycare centers, preschools, and other unavoidable group settings, we all know that the number of young children infected with omicron will soar exponentially, creating the largest health risk that kids have faced collectively throughout the entire pandemic,” the doctors wrote in their letter.

At least 1,000 children have died from Covid since the pandemic began in 2020, according to CDC data, and hospitals have seen more than 94,000 admissions of children with Covid, according to the data. The virus has infected more than 11.4 million children, representing 18.6% of all cases since the pandemic began, according to the American Academy of Pediatrics.

More than 6,000 children have developed multisystem inflammatory syndrome known as MIS-C, according to the CDC. MIS-C is a rare, but serious, condition associated with Covid that is characterized by the inflammation of multiple organ systems. At least 55 children have died from MIS-C, according to CDC data.

Dr. Grace Lee, a professor of pediatrics at Stanford University, said the pandemic has burdened an entire generation of children, with the long-term impact yet to be seen.

“I also truly believe we have not yet addressed the long-term impact of Covid infection in children,” Lee told the CDC’s independent committee of vaccines advisors, which she chairs, earlier this month just before the agency cleared Pfizer boosters for 12- to 15-year-old children.

“I think we haven’t even scratched the surface of what we’re going to see,” Lee said.

Next Post

AMD rises nearly 10% after issuing strong 2022 sales outlook

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:

By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

Popular Posts

Stock News

Bitcoin, ether build on recent gains as investors await Fed rate hike decision

by
March 21, 2023
0

Pedestrians walk past an advertisement displaying a Bitcoin cryptocurrency token on February 15, 2022 in Hong Kong, China. Anthony Kwan...

Read more

Bitcoin, ether build on recent gains as investors await Fed rate hike decision

Potentially deadly fungus is spreading at an ‘alarming rate,’ CDC says

Cathie Wood says rising rates hit her strategy like an earthquake and cyclical stocks are next

Home sales spike 14.5% in February as the median price drops for the first time in over a decade

GameStop stock soars after retailer posts first quarterly profit in two years

Bill Gates says OpenAI’s GPT is the most important advance in technology since 1980

Load More

All rights reserved by www.dividendstocksreport.net

  • Home
  • Stock News
  • Privacy Policy
  • Email Whitelisting
No Result
View All Result
  • Home
  • Stock News
  • Privacy Policy
  • Email Whitelisting

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.